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Abstract
Introduction Our aim was to study the expression pattern of
tissue inhibitor of metalloproteinases (TIMP)-3 protein in
invasive breast carcinoma, and its clinicopathological and
prognostic value as well as its relation to markers indicative of
the tumor phenotype.
Methods Immunohistochemistry was performed on paraffin-
embedded tissue specimens from 173 invasive breast
carcinomas to detect the proteins TIMP-3, estrogen receptor
(ER), progesterone receptor, p53, c-erbB-2, topoisomerase IIα
and Bcl-2.
Results TIMP-3 protein was immunodetected in the cytoplasm
of the malignant cells and the peritumoral stroma, as well as in
in situ carcinoma and normal epithelium. Reduced expression of
TIMP-3 protein within cancer cells was correlated with
carcinomas of high nuclear and histological grade (p = 0.032
and  p  = 0.015, respectively), and low ER expression (p  =
0.053). Moreover, TIMP-3 immunopositivity was inversely
correlated with the expression of p53 and topoIIα proteins (p =
0.002 and p = 0.008, respectively), whereas it was positively
associated with Bcl-2 expression (p  = 0.020). Reduced
expression of TIMP-3 protein within cancer cells was found to
have an unfavorable impact on disease-free survival (p = 0.052)
in the entirety of the patient population, as well as in both
subgroups of lymph-node-positive and mutant-p53-negative
patients (p  = 0.007 and p  = 0.037, respectively). Stromal
localization of TIMP-3 protein was found to have no
clinicopathological or prognostic value.
Conclusion This is the first immunohistochemical study to show
that TIMP-3 protein within cancer cells is associated with tumor
phenotype. Reduced expression of TIMP-3 protein within
cancer cells was found to correlate with an aggressive tumor
phenotype, negatively affecting the disease-free survival of both
subgroups of lymph node-positive and mutant-p53-negative
patients.
Introduction
Matrix metalloproteinases (MMPs) consist of a family of pro-
teases that have a major role in the remodeling and turnover of
the extracellular matrix, which is involved in many physiological
and pathological conditions including tumor growth and
metastasis [1]. Tissue inhibitors of metalloproteinases (TIMPs)
are natural MMP inhibitors and impede the proteolytic activity
of MMPs by forming noncovalent 1:1 stoichiometric com-
plexes [2]. Disruption of the balance between MMPs and
TIMPs may influence invasion and metastasis of cancer and
may thus modify patient outcome [1]. However, TIMPs exhibit
several other biological functions in addition to the inhibition of
active MMPs. These include the regulation of pro-MMP activa-
tion, tumor angiogenesis, cell growth and apoptosis [3].
ER = estrogen receptor; MMP = matrix metalloproteinase; PR = progesterone receptor; TIMP = tissue inhibitor of metalloproteinases.Breast Cancer Research    Vol 8 No 5    Mylona et al.
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Table 1
Correlation of TIMP-3 protein expression with clinicopathological parameters and various biological markers.
Parameter Total Preserved expression
TIMP-3 within cancer cells Fibroblastic TIMP-3
n % pn% p
Menopausal status
Before 52 19 36.5 NS 25 48.1 NS
After 115 41 35.7 53 46.1
Histological type
Ductal 133 46 34.6 NS 61 45.9 NS
Lobular 33 14 42.4 17 51.5
Histological grade
1 21 12 57.1 0.015 12 54.5 NS
2 98 36 36.7 44 44.9
3 43 9 20.9 19 44.2
Nuclear grade
1 58 28 48.3 0.032 27 46.6 NS
2 55 19 34.5 25 44.6
3 53 13 24.5 26 49.1
Tumor size
<2 39 19 48.7 NS 20 51.3 NS
2 to 5 101 35 34.7 43 42.2
>5 26 6 23.1 15 57.7
LN status
Not infiltrated 65 24 36.9 NS 30 45.5 NS
Infiltrated 100 36 36.0 48 48.0
Stage
1 29 13 44.8 NS 15 51.7 NS
2 108 40 37.0 47 43.1
3 28 7 25.0 16 57.1
ER status
Negative 75 21 28.0 0.053 35 46.7 NS
Positive 91 39 42.9 43 46.7
PR status
Negative 84 28 33.3 NS 40 47.6 NS
Positive 82 32 39.0 38 45.8
p53 status
Negative 118 51 43.2 0.002 57 47.9 NS
Positive 46 8 17.4 19 41.3
Bcl-2 status
Negative 54 16 29.6 0.02 29 53.7 NS
Positive 79 40 50.6 41 51.3
c-erbB-2 status
Negative 62 18 29.0 NS 25 39.7 NSAvailable online http://breast-cancer-research.com/content/8/5/R57
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TIMP-3 is one of the four known TIMPs (TIMP-1, TIMP-2,
TIMP-3 and TIMP-4). It is known to be tightly bound to the
matrix through interaction with heparan sulphate [4] The gene
encoding TIMP-3 is a cell-cycle-regulated gene [5] whose pro-
moter has been shown to be regulated by cell-cycle-related
factors such as p53 [6]. In vitro studies have shown that TIMP-
3 can suppress invasion [7-9] and may either promote [10] or
inhibit [7,11] cell growth as well inducing apoptosis in cancer-
ous [8,9,11,12] and non-cancerous [7] cells. Specifically, the
latter is associated with death receptor modulation [12,13]
and type II apoptotic pathway activation [12]. Interestingly, at
least in the mouse, it has been demonstrated that the absence
of TIMP-3 is important in regulating apoptosis in physiological
processes [14]. Moreover, delivery of TIMP-3 to tumor
xenografts has confirmed its tumor suppressive activity
[11,15]. Studies on silencing of TIMP-3 by gene methylation
also suggested a tumor suppression role in several malignan-
cies [16].
TIMP-3 expression has been detected in several cancer types,
including esophageal [17,18], colorectal [19], endometrial
[20] and prostatic [21] cancer. However, in breast cancer,
TIMP-3 mRNA was found by in situ hybridization to be
expressed predominantly in the peritumoral stroma [22],
whereas its clinicopathological and prognostic value has been
evaluated in relation to the expression levels of TIMP-3 mRNA
and measured by methods that did not distinguish the cancer-
ous from the stromal origin of the transcripts [23,24].
The purpose of the present study was to investigate the
expression pattern of TIMP-3 protein in invasive breast carci-
noma to determine the clinicopathological and prognostic
value of its various localizations and their relation to the tumor's
phenotype through their association with biological indicators,
such as the cell cycle-related proteins p53 and topoisomerase
IIα (topoIIα), c-erbB-2 and the anti-apoptotic protein Bcl-2.
Materials and methods
Patients and samples studied
A total of 173 paraffin blocks with tumor samples were availa-
ble from patients with resectable breast cancer, who had
undergone surgery. We selected only women with histologi-
cally proven, clearly invasive breast carcinomas, regardless of
their initial stage, in whom axillary lymph node dissection had
been performed and who had all their resected materials stud-
ied histologically. The patients were aged from 25 to 86 years
(mean 56.89 years). None of them had received radiation or
chemotherapy preoperatively. The material acquired from
them was used in research after informed consent had been
obtained.
Routine histological examination was performed with hematox-
ylin–eosin staining. All carcinomas were classified in accord-
ance with the criteria of the World Health Organization [25]
and were recorded as invasive ductal or invasive lobular. The
combined histological grade (1, 2 or 3) of infiltrating ductal
carcinoma was obtained according to a modified Scarff–
Bloom–Richardson histological grading system with guide-
lines as suggested by Nottingham City Hospital pathologists
[26]. Nuclear grading was based on nuclear pleomorphism.
Staging at the time of diagnosis was based on the TNM sys-
tem [27]. Tumor size (less than 2 cm, 2 to 5 cm, more than 5
cm) and lymph node status were evaluated separately. The
clinicopathological characteristics of the series are shown in
Table 1. During the immunohistochemical procedure some
specimens were destroyed, whereas others were considered
to have too little tissue to be evaluated. The samples that were
finally included in the statistical evaluation therefore numbered
167.
Follow-up was available for 166 patients, of whom 39 died of
breast cancer and 109 had a recurrence. Mean survival time
was 96.7 months (range 5 to 135 months) and median survival
time was 111 months. Patient outcome was defined as dis-
ease-specific overall survival and recurrence-free survival, from
surgery. All patients received conventional postoperative treat-
ment depending on the extent of the disease, including radia-
tion therapy and medical antiestrogen therapy, when
indicated. Premenopausal patients with axillary involvement
were treated with six courses of adjuvant chemotherapy.
Immunohistochemistry
Immunohistochemical staining for TIMP-3 was performed on
formalin-fixed paraffin sections 4 µm thick after heating
overnight at 37°C and subsequent deparaffinization in xylene
and rehydration through graded alcohols. After the quenching
of endogenous peroxidase activity with 0.3% hydrogen perox-
ide in Tris-buffered saline for 30 minutes, we proceeded to
microwave-mediated antigen retrieval in 10 mM citrate buffer
(pH 6.0) at 750 W for 15 minutes (three cycles, 5 minutes
each). After rinsing with Tris-buffered saline, normal horse
serum was applied for 30 minutes to block non-specific anti-
body binding. Subsequently, sections were incubated over-
night at 4°C with the primary antibodies. A two-step technique
(Envision; Dako, Glostrup, Denmark) was used for visualiza-
tion, with diaminobenzidine as a chromogen. Finally, sections
were counterstained with hematoxylin and mounted.
Positive 104 42 40.4 53 51.0
ER, estrogen receptor; LN, lymph node; NS, not significant; PR, progesterone receptor; TIMP, tissue inhibitor of metalloproteinases.
Table 1 (Continued)
Correlation of TIMP-3 protein expression with clinicopathological parameters and various biological markers.Breast Cancer Research    Vol 8 No 5    Mylona et al.
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A rabbit polyclonal antibody against the C terminus of human
TIMP-3 (no. RB-1541; Neomarkers, Fremont, CA, USA) was
used at a dilution of 1:70. For the detection of estrogen recep-
tor (ER) and progesterone receptor (PR), p53, c-erbB-2, Bcl-
2 and topoisomerase IIα proteins we used the following anti-
bodies overnight, in a process similar to the aforementioned:
anti-ER, clone 1D5 (dilution 1:450; Dako); anti-PR, clone IA6
(dilution 1:150; Dako); anti-p53, clone BP 53.12.1 (dilution
1:50; Oncogene, Cambridge, MA, USA); anti-c-erbB-2, clone
CB11 (dilution 1:150; Biogenex, San Ramon, CA, USA); anti-
Bcl-2, clone 124 (dilution 1:120; Dako, Glostrup, Denmark);
and anti-topoIIα, clone JH2.7 (dilution 1:100; Biocare Medical,
Walnut Creek, CA, USA).
Evaluation of immunohistochemistry
Evaluation of the immunohistochemical staining was per-
formed independently by two pathologists through light micro-
scopic observation and without knowledge of the clinical data
for each patient. Cases of disagreement were reviewed jointly
to reach a consensus score. The score was the average from
10 distinct high-power fields observed under ×400 magnifica-
tion. As positive controls we used both a placenta section pre-
viously known to be TIMP-3 immunoreactive (external control)
as well as normal ductal epithelial cells and in situ components
adjacent to cancer tissues (internal staining control). These in
particular stained with high intensity, comparable to that of the
external staining control. Negative controls had the primary
antibody omitted and replaced by nonimmune normal serum
from the same species as the primary antibody or by Tris-buff-
ered saline.
TIMP-3 was detected in the cytoplasm of the malignant cells
and the peritumoral stroma. Staining intensity and the number
of stained cells were taken into consideration all through the
evaluation process, and cytoplasmic staining in tumor cells
and the peritumoral fibroblasts was scored on a scale of 0 to
3 in half steps, as described previously [28]. A score of 0 was
given when no staining was detected, 1 if there was weak to
moderate staining in less than 10% of cells, 2 if moderate to
strong staining was present in 11 to 50% of cells, and 3 if
strong staining in more than 50% of cells was detected. TIMP-
3 was strongly expressed in internal positive controls. TIMP-3
protein staining in tumor cells fell into two distinct groups:
those with expression equal to or reduced in relation to the
internal positive staining controls. Tumor TIMP-3 staining was
separated into these categories for the purposes of statistical
analysis.
Staining for ER and PR was evaluated semiquantitatively with
the H score system; a score of more than 50 was considered
positive for both antigens [29]. Evaluation of the immunostain-
ing of p53, c-erbB-2, Ki67 and topoIIa proteins was performed
as described previously [30,31]. Because topoIIα immunopo-
sitive cells were rare, the percentage of 500 neoplastic cells
that were positive for topoIIα was determined by image analy-
sis [30].
Figure 1
TIMP-3 protein expression in breast cancer and normal epithelium TIMP-3 protein expression in breast cancer and normal epithelium. The micrographs show tissue inhibitor of metalloproteinases (TIMP)-3 in the cyto-
plasm of a lobular carcinoma (a), both the cancer cells and peritumoral stroma of a ductal carcinoma (b), in situ carcinoma (c) and normal epithelium 
(d). Envision/horseradish peroxidase staining; original magnification ×200.Available online http://breast-cancer-research.com/content/8/5/R57
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Statistics
The significance of the relationship between the expression of
TIMP-3 and clinicopathological parameters was evaluated by
univariate analysis with a χ2 test and Fisher's exact probability
test. TopoIIα expression failed to fit the Gaussian distribution.
We therefore used nonparametric analysis of variance with
ranks to assess the relationship of the aforementioned markers
to topoIIa. The effect of TIMP-3 differential expression on post-
operative survival rates was assessed with both univariate
(log-rank test) and multivariate (stepwise forward Cox's pro-
portional-hazards regression model) analysis; p ≤ 0.05 was
considered statistically significant.
Results
TIMP-3 protein was immunodetected in the cytoplasm of the
malignant cells and the peritumoral fibroblasts in 35.9% and
56.4% of cases, respectively (Figure 1a, b). In the cases
where in situ carcinoma or normal epithelium were present,
they demonstrated an intense immunopositivity for TIMP-3
(Figure 1c, d). Reduced expression of cancerous TIMP-3 pro-
tein was correlated with carcinomas of high nuclear and histo-
logical grades (p  = 0.032 and p  = 0.015, respectively).
Moreover, TIMP-3 expression was weakly associated with ER
expression (p = 0.053), whereas no correlation was found
between cytoplasmic TIMP-3 and the rest of the clinicopatho-
logical parameters (Table 1). Tumor-cell-associated TIMP-3
was inversely correlated with p53 (p = 0.002) and topoIIα (p
= 0.008, Figure 2), and was positively correlated with Bcl-2
expression (p = 0.020). No correlation between TIMP-3 and c-
erbB-2 status was observed (Table 1).
With regard to patient outcome, reduced TIMP-3 expression
within cancer cells was weakly correlated with reduced recur-
rence-free survival in the overall patient population by univari-
ate analysis (p = 0.052; Figure 3a). Moreover, reduced TIMP-
3 in cancer cells was associated with reduced recurrence-free
survival in the 100 lymph-node-positive cases (p = 0.007; Fig-
ure 4a) and in the subset of 118 p53-negative cancers (p =
0.037; Figure 4b). However, cancer-cell-associated TIMP-3
was not prognostic for disease-specific overall survival in the
entire patient population (Figure 3b) or in any patient subset
(data not shown). Nor was TIMP-3 prognostic after multivari-
ate analysis. Indeed, only tumor stage was an independent
indicator for recurrence-free (hazard ratio 4.0, 95% confi-
dence interval 2.3 to 7.1, p < 0.0001) or disease-specific
overall survival (hazard ratio 5.0, 95% confidence interval 2.5
to 10.1, p < 0.0001) after adjusting for age, therapy received
and all other factors listed in Table 1. Unlike cancer-cell-asso-
ciated TIMP-3, TIMP-3 expression within fibroblasts had no
prognostic power (data not shown), nor was it associated with
any clinicopathological factor (Table 1).
Discussion
This is the first immunohistochemical study investigating the
clinicopathological and prognostic significance of the various
localizations of TIMP-3 protein expression. In the present
study, TIMP-3 protein was immunodetected in the cytoplasm
of both malignant cells and peritumoral fibroblasts. This is con-
sistent with studies that reported the same localizations in
esophageal [17], colorectal [19] and endometrial cancers
[20]. Moreover, the fact that we detected TIMP-3 protein in a
larger percentage of cases in the peritumoral fibroblasts than
in malignant cells agrees with Byrne and colleagues [22] who,
by in situ mRNA hybridization, found TIMP-3 gene to be pre-
dominantly expressed by fibroblastic cells within the tumor
stroma. Furthermore, we found TIMP-3 protein to be
expressed in both normal epithelium and the in situ compo-
nent, where they existed adjacent to the cancerous tissue. This
is consistent with the observation of Darnton and colleagues
[17], who immunodetected TIMP-3 in normal and metaplastic
esophageal epithelium as well as in esophageal
adenocarcinoma.
In the present study, reduced expression of TIMP-3 protein
was correlated with tumors of higher nuclear and histological
grades; in other words, tumors of poor differentiation that usu-
ally display a more aggressive biological behavior. This is the
first study to report a relationship between TIMP-3 expression
and the grade of tumor differentiation. To our knowledge, only
two other studies have investigated TIMP-3 expression in
breast cancer [23,24] and they found no correlation with any
clinicopathological parameter. This discrepancy from our find-
ings may be assigned to the different methodology used. Spe-
cifically, both groups of authors used polymerase chain
reaction to assess TIMP-3 mRNA expression levels in tumor
Figure 2
Relation between the expression of TIMP-3 and topoIIα proteins Relation between the expression of TIMP-3 and topoIIα proteins. 
Graphic representation of the relationship between tissue inhibitor of 
metalloproteinases (TIMP)-3 in cancer cells and topoIIα protein 
expressions.Breast Cancer Research    Vol 8 No 5    Mylona et al.
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tissue, without distinguishing whether mRNA comes from the
malignant cells or the surrounding stromal cells.
The aforementioned association of the reduced expression of
TIMP-3 protein with an aggressive tumor phenotype is further
supported by its correlation with the expression of the mutant
p53 and topoIIα proteins. The wild-type gene encoding p53 is
a tumor suppressor gene whose protein product regulates the
cell cycle checkpoint in response to DNA damage [32]. Muta-
tions in this gene, which deactivate its growth-suppressing
activities, have been observed in most human tumors. Here it
is considered to participate not only in the acquisition of the
transformed phenotype but also in the process of cancer pro-
gression from benign to metastatic [33]. The inverse correla-
tion between TIMP-3 protein expression and mutant p53 is
consistent with the studies that have shown that expression of
the gene encoding TIMP-3 is repressed in cells expressing
mutant p53 alleles [6].
TopoIIα is a proliferation marker that is considered to estimate
the number of actively cycling cells [34]. The inverse associa-
tion of TIMP-3 protein with a proliferation marker is in line with
its inverse correlation with nuclear grade, because the number
of mitoses is coevaluated in the assessment of tumor's nuclear
grade. Moreover, it agrees with studies that have shown TIMP-
3 overexpression to inhibit the increase in cell number in vitro
[7,11]. In other words, according to our findings, reduced
TIMP-3 expression seems to be related to cell cycle deregula-
tion and tumor cell proliferation, further contributing to the
development of an aggressive tumor phenotype.
Bcl-2 is a negative regulator of apoptosis-specific mitochon-
drial functions [35]. In the present study we found a positive
correlation between TIMP-3 protein expression and the
antiapoptotic index Bcl-2, thus suggesting the involvement of
TIMP-3 protein in apoptosis suppression. Contrary to our find-
ings, TIMP-3 has been shown to promote apoptosis [8,9,11-
13] in an MMP-independent mechanism [11]. However, and in
accordance with our findings, TIMP-3-/- mice have been shown
to display accelerated postlactational epithelial cell apoptosis
[14], suggesting that the presence of TIMP-3 in the mammary
gland is presumably associated with reduced apoptosis.
Figure 3
The prognostic significance of TIMP-3 protein expression in the entire patient population The prognostic significance of TIMP-3 protein expression in the entire patient population. The graphs show the effect of tissue inhibitor of metallo-
proteinases (TIMP)-3 expression on patient recurrence-free (a) and disease-specific overall (b) survival (log-rank test).
Figure 4
The prognostic significance of TIMP-3 protein expression in the LN+ and p53- patient subgroups The prognostic significance of TIMP-3 protein expression in the LN+ and p53- patient subgroups. The graphs show the impact of tissue inhibitor of 
metalloproteinases (TIMP)-3 on the recurrence-free survival of the lymph-node (LN)-positive (a) and mutant-p53-negative (b) patients (log-rank test).Available online http://breast-cancer-research.com/content/8/5/R57
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Moreover, in the present study we discovered a positive corre-
lation between TIMP-3 protein within cancer cells and ER. This
finding is in line with that of Span and colleagues [23] and
Kotzsch and colleagues [24], who also reported TIMP-3
mRNA levels to be higher in steroid hormone receptor-positive
samples, and yet not in accord with other studies that
demonstrated that estradiol induced a decrease in TIMP-3 in
uterine tissue [36] or nulliparous murine mammary gland [37].
As regards survival rate, decreased expression of TIMP-3
within the cytoplasm of cancer cells was associated with poor
disease-free survival of our patients. This is in accord with the
observation that overexpression of TIMP-3 in tumor cells inhib-
its invasion, a function consistent with its role as an MMP
inhibitor, and induces apoptosis in vitro [8,9]. Our finding was
of weak statistical significance and failed to be confirmed in
multivariate analysis, differing from both Span and colleagues
[23], who found no prognostic significance for TIMP-3 mRNA
levels, and Kotzsch and colleagues [24], who showed low
TIMP-3 mRNA levels to be an independent poor prognostica-
tor of patient disease-free survival. This may be due to the dif-
ferences in the methods used or it may reflect the weak rather
than the strong prognostic power of TIMP-3 and the modest
number of cases examined. However, in subgroup analyses,
decreased immunoexpression of TIMP-3 protein was found to
be a significant prognostic indicator of an unfavorable recur-
rence-free survival in both subgroups of lymph-node-positive
and mutant-p53-negative patients. This probably suggests
that TIMP-3, as an invasion suppressor, may have a major role
in patients with positive lymph nodes in whom the invasive
process has been already activated. Moreover, the fact that in
our study TIMP-3 was weakly associated with outcome but
was fairly strongly associated with p53 status, in combination
with the studies suggesting that p53 suppresses TIMP-3
expression, makes one think that TIMP-3 association with out-
come may merely be a reflection of p53 status rather than any
causal effects that it might have on cancer progression. In
other words, p53 may be driving both progression and tumor-
associated TIMP-3 expression. However, it is notable that
TIMP-3 was still prognostic in the p53-negative subset of
cases, suggesting that its correlation with outcome may not
merely reflect p53 status but may indeed have an active role in
suppressing cancer progression.
Finally, the fact that TIMP-3 protein within fibroblasts was
found to have no clinicopathological or prognostic value indi-
cates that, at least in our series of tumor samples, TIMP-3
within cancer cells seems to be more strongly correlated with
tumor biological behavior than stromal TIMP-3. Besides,
although TIMP-3 has been shown to be bound to the extracel-
lular matrix, to our knowledge there are no studies to elucidate
the locations at which TIMP-3 protein takes action.
Conclusion
This is the first immunohistochemical study to show that, of the
two tissue localizations of TIMP-3 protein, cancer and stromal,
the one within the cancer cells seems to have a more active
role in the modulation of tumor phenotype. Thus, decreased
expression of TIMP-3 protein within cancer cells seems to be
associated with an aggressive tumor phenotype through its
correlations with nuclear and histological grade, expression of
the proliferation marker topoIIα and expression of the apopto-
sis-related indicators, mutant p53 and Bcl-2. Moreover,
reduced expression of TIMP-3 was found to be a significant
prognostic indicator of shortened disease-free survival in the
lymph-node-positive and mutant-p53-negative patients, indi-
cating that immunodetection of TIMP-3 protein could improve
the prediction of disease recurrence in some subgroups of
patients with invasive breast cancer.
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